PRE JAY HOLDINGS LTD and WOCO INVESTMENTS LTD

Link copied
Case Copied 12 min read

OFFICIAL NOTICE

DECISION OF A DELEGATE OF THE COMMISSIONER OF PATENTS

Patent:          No. 582540 in the name of PRE JAY HOLDINGS LIMITED and WOCO INVESTMENTS LTD

Title:          A Method of Hormonal Treatment of Perimenopausal, Menopausal and Post-menopausal Disorders and Multi-preparation Pack therefor.

Action: Application for an extension of term of a pharmaceutical patent under section 70 of the Patents Act.

Decision:          Issued            .

Abstract

It was found that the pharmaceutical substance, PREMIA 2.5 CONTINUOUS, per se was in substance disclosed in the complete specification.  However, all the claims are to methods of treatment and it was found that the pharmaceutical substance per se does not in substance fall within the scope of the claim or claims of the specification. As a result, the section 70 application for extension of term of patent 582540 was refused for failing to comply with section 70(2)(a).

PATENTS ACT 1990

DECISION OF A DELEGATE OF THE COMMISSIONER OF PATENTS

Re:Patent No. 582540 by Pre Jay Holdings Limited and Woco Investments Ltd and an application under section 70 of the Patents Act for an extension of term of a patent relating to pharmaceutical substances

BACKGROUND

This decision concerns an application filed on 27 July 1999 by Pre Jay Holdings Limited and Woco Investments Ltd (hereafter referred to as "the patentee") for an extension of term of their patent number 582540.  The patent was granted on 28 July 1989 and its 20 year term is due to expire on 1 August 2004.

The information supplied with the application for extension of term indicated that goods containing the substance PREMIA 5 were listed on the Australian Register of Therapeutic Goods (ARTG) but no certificate of registration was provided. The first regulatory approval date for this product was given as 12 June 1997. Subsequently, the patentee realised that the section 70 application had been based on the wrong product and that the correct product should have been PREMIA 2.5, which also has a first regulatory approval date of 12 June 1997. A second section 70 application, accompanied by the certificate of registration for PREMIA 2.5, was then made on 24 December 1999. In order to comply with the timing requirements set out in section 71(2), the patentee applied for, and was granted, an extension of time under section 223 for making the section 70 application.

An examiner's notice of deficiency on the second section 70 application was issued on 6 July 2000 in which the examiner indicated that the application does not comply with the requirements of section 70(2). Following further correspondence between the examiner and the patentee's attorney, the matter was set for hearing. The patentee chose not to appear but instead relied on 2 pages of written submissions dated 26 February 2001 from their patent attorney, Mr David Gibson from Freehills Carter Smith Beadle.

THE SPECIFICATION

The specification describes the invention as relating to a method of hormonal treatment for menopausal (including perimenopausal and post-menopausal) disorders in women and, particularly, a treatment involving…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read PRE JAY HOLDINGS LTD and WOCO INVESTMENTS LTD and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2001] APO 18
Decision Date

CaseChat Overview and Summary

The case concerns an application by Pre Jay Holdings Limited and Woco Investments Ltd for an extension of term for their patent number 582540. The patent, which was granted on 28 July 1989, covers a method of hormonal treatment for perimenopausal, menopausal, and post-menopausal disorders and is due to expire on 1 August 2004. The application was initially based on the wrong product, PREMIA 5, but was later corrected to include the correct product, PREMIA 2.5 CONTINUOUS. The application for extension of term was made under section 70 of the Patents Act, which allows for an extension if certain conditions are met. The primary legal issue was whether the pharmaceutical substance in question, PREMIA 2.5 CONTINUOUS, met the requirements of section 70(2)(a) of the Act.

The court found that while PREMIA 2.5 CONTINUOUS was indeed disclosed in the specification, all the claims in the patent were directed to methods of treatment, not to the pharmaceutical substance itself. The court concluded that for an extension to be granted under section 70(2)(a), there must be at least one claim to a pharmaceutical substance per se, which is unqualified by process or method components. As the patent only contained method claims, the court ruled that the pharmaceutical substance per se did not fall within the scope of the claims, and therefore the application for an extension of term was refused.

In summary, the court determined that the application for an extension of term of the patent was not valid because the pharmaceutical substance per se did not satisfy the requirements of section 70(2)(a) of the Patents Act. Consequently, the request for an extension of term of patent 582540 was refused.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.